Kyle Gano, Chief Executive Officer and Director of Neurocrine Biosciences Inc, filed a Form 4 on November 3, 2026, disclosing transactions in common stock and restricted stock units dated November 1, 2026.

Key Highlights

  • RSU vesting: 614 restricted stock units vested on November 1, 2026, acquired at $0 per share (transaction code M), bringing total direct common stock holdings to 155,342 shares immediately after the vesting.
  • Tax withholding: 332 shares were withheld by Neurocrine Biosciences to satisfy tax withholding requirements on the RSU vesting at a price of $146.10 per share; according to the filing, no shares were sold.
  • Post-transaction ownership: Following both transactions, Gano directly owned 155,010 shares of common stock.
  • Remaining RSU balance: After the November 1, 2026 vesting, 1,228 restricted stock units remain beneficially owned by the reporting person.
  • Original grant: The RSU award was granted on November 1, 2024, with vesting of 613 shares on November 1, 2025, 614 shares on November 1, 2026, and scheduled vesting of 614 shares on each of November 1, 2027 and November 1, 2028, subject to award terms and conditions.
  • Issuer: Neurocrine Biosciences Inc, trading on NASDAQ:NBIX.

Neurocrine Biosciences CEO RSU Vesting and Share Withholding Details

According to the Form 4 filed with the SEC on November 3, 2026, Kyle Gano, who serves as both Chief Executive Officer and Director of Neurocrine Biosciences Inc (NASDAQ:NBIX), reported two transactions in the company's common stock on November 1, 2026. The first was the acquisition of 614 shares through the vesting of restricted stock units at $0 cost (transaction code M). Immediately following that acquisition, the filing shows Gano held 155,342 shares of common stock directly.

The second transaction, coded F, reflects the withholding of 332 shares by the company to cover tax obligations arising from the RSU vesting, at a price of $146.10 per share. The filing states explicitly that "no shares were sold." After this withholding, Gano's direct beneficial ownership in common stock stood at 155,010 shares, as reported in the filing.

The filing further discloses that the underlying RSU award was originally granted on November 1, 2024. The grant vested 613 shares on November 1, 2025 and 614 shares on November 1, 2026. According to the filing, the award is scheduled to vest an additional 614 shares on November 1, 2027 and 614 shares on November 1, 2028, "subject to the terms and conditions of the award." Following the November 1, 2026 vesting, the reporting person holds 1,228 RSUs, each representing a contingent right to receive one share of the issuer's common stock. The Form 4 was signed by Darin Lippoldt as Attorney-in-Fact on November 3, 2026.

What Was Disclosed

Neurocrine Biosciences CEO Kyle Gano reported the vesting of 614 RSUs and the withholding of 332 shares for taxes on November 1, 2026. Following these transactions, he directly held 155,010 shares of common stock and 1,228 remaining RSUs.